Donors Health Dictionary

  1. Health Encyclopedia
  2. Donors

Donors: From 1 Different Sources

People who donate parts of their bodies for use in other people. Many organs and tissues can be donated – most commonly blood, but skin, corneas, kidneys, livers and hearts can all be used. Combined heart and lung transplants are being increasingly used for patients with severe lung diseases, and, if the recipients have a condition such as CYSTIC FIBROSIS in which the heart is normal, it is sometimes possible for them to receive a heart and lungs from one donor and to donate their own heart to someone else. Recent work has explored the possibility of using pancreatic transplants. Apart from blood, it is unusual for tissue to be taken from living donors. Skin, small pieces of liver, and a kidney can, in theory, be obtained from living donors, but the ETHICS of this are hotly debated and the situations under which it may be done are tightly controlled. Because transplanted organs are seen by the receiving body as ‘foreign bodies’, careful matching before transplantation is necessary to avoid rejection, and immunosuppressive drugs may be required for some time after the operation to prevent this from occurring.

There are strict regulations about how death should be diagnosed before organs can be removed for transplantation, and potential donors must satisfy the BRAIN-STEM DEATH criteria, performed twice by two doctors who are independent of the transplant team. There is a great shortage of suitable organs for donation – partly because they must be in excellent condition if the operation is to be a success. Some medical conditions or modes of death make people unsuitable as organ donors; this makes it all the more important that people should be encouraged to donate their organs. People who wish to do so can carry a special card indicating their willingness to become donors in the event of their death. These cards can be obtained from various sources, including hospitals, GPs’ surgeries and many public buildings such as libraries. In the UK, informed positive approval from the patient, or relatives, is required.

Information about becoming a blood donor can be obtained by telephoning 0845–7 711

711. Those who wish to bequeath their bodies for dissection purposes should get in touch with HM Inspector of Anatomy. Other would-be organ donors may contact the British Organ Donor Society.

Health Source: Medical Dictionary
Author: Health Dictionary

Artifact (artefact)

A foreign body found in living tissue viewed under a microscope. It is usually caused by faulty preparation of a specimen, with the result that disease or abnormality seems to be present.

Arti?cial Insemination

In this method of fertilisation, SEMEN is collected either by the husband (AIH) or by a donor (AID) through masturbation and introduced into the cervix (neck of the womb) by means of an instrument around the time of OVULATION.

AIH is thought to be particularly useful for men with retrograde ejaculation or erectile IMPOTENCE. AID may be considered when the partner’s sperm count is either very low or zero.

Insemination can be made with fresh or frozen semen. Donors should be tested for sexually transmitted diseases and their identity remain unknown to the infertile couple. The pregnancy rate over six months is 50–60 per cent. Arti?cial insemination is usually done at specially sta?ed centres with facilities to store semen and provide the individuals involved with appropriate counselling. Success rates are up to 70 per cent with fresh semen (used over a six-month period) and over 50 per cent with frozen semen.... artifact (artefact)

Assisted Conception

(Further information about the subject and the terms used can be found at http:// www.hfea.gov.uk/glossary)

This technique is used when normal methods of attempted CONCEPTION or ARTIFICIAL INSEMINATION with healthy SEMEN have failed. In the UK, assisted-conception procedures are governed by the Human Fertilisation & Embryology Act 1990, which set up the Human Fertilisation & Embryology Authority (HFEA).

Human Fertilisation & Embryology Act 1990 UK legislation was prompted by the report on in vitro fertilisation produced by a government-appointed committee chaired by Baroness Warnock. This followed the birth, in 1978, of the ?rst ‘test-tube’ baby.

This Act allows regulation monitoring of all treatment centres to ensure that they carry out treatment and research responsibly. It covers any fertilisation that uses donated eggs or sperm (called gametes) – for example, donor insemination or embryos (see EMBRYO) grown outside the human body (known as licensed treatment). The Act also covers research on human embryos with especial emphasis on foolproof labelling and immaculate data collection.

Human Fertilisation & EmbryologyAuthority (HFEA) Set up by the UK government following the Warnock report, the Authority’s 221 members inspect and license centres carrying out fertilisation treatments using donated eggs and sperm. It publishes a code of practice advising centres on how to conduct their activities and maintains a register of information on donors, patients and all treatments. It also reviews routinely progress and research in fertility treatment and the attempted development of human CLONING. Cloning to produce viable embryos (reproductive cloning) is forbidden, but limited licensing of the technique is allowed in specialist centres to enable them to produce cells for medical treatment (therapeutic cloning).

In vitro fertilisation (IVF) In this technique, the female partner receives drugs to enhance OVULATION. Just before the eggs are released from the ovary (see OVARIES), several ripe eggs are collected under ULTRASOUND guidance or through a LAPAROSCOPE. The eggs are incubated with the prepared sperm. About 40 hours later, once the eggs are fertilised, two eggs (three in special circumstances) are transferred into the mother’s UTERUS via the cervix (neck of the womb). Pregnancy should then proceed normally. About one in ?ve IVF pregnancies results in the birth of a child. The success rate is lower in women over 40.

Indications In women with severely damaged FALLOPIAN TUBES, IVF o?ers the only chance of pregnancy. The method is also used in couples with unexplained infertility or with male-factor infertility (where sperms are abnormal or their count low). Women who have had an early or surgically induced MENOPAUSE can become pregnant using donor eggs. A quarter of these pregnancies are multiple – that is, produce twins or more. Twins and triplets are more likely to be premature. The main danger of ovarian stimulation for IVF is hyperstimulation which can cause ovarian cysts. (See OVARIES, DISEASES OF.)... assisted conception

Corneal Graft

Also known as keratoplasty. If the cornea (see EYE) becomes damaged or diseased and vision is impaired, it can be removed and replaced by a corneal graft. The graft is taken from the cornea of a human donor. Some of the indications for corneal grafting include keratoconus (conicalshaped cornea), corneal dystrophies, severe corneal scarring following HERPES SIMPLEX, and alkali burns or other injury. Because the graft is a foreign protein, there is a danger that the recipient’s immune system may set up a reaction causing rejection of the graft. Rejection results in OEDEMA of the graft with subsequent poor vision. Once a corneal graft has been taken from a donor, it should be used as quickly as possible. Corneas can be stored for days in tissue-culture medium at low temperature. A small number of grafts are autografts in which a patient’s cornea is repositioned.

The Department of Health has drawn up a list of suitable eye-banks to which people can apply to bequeath their eyes, and an o?cial form is now available for the bequest of eyes. (See also DONORS; TRANSPLANTATION.)... corneal graft

National Blood Authority

This body manages regional TRANSFUSION centres. Among its aims are the maintenance and promotion of blood and blood products based on a system of voluntary donors; implementing a cost-e?ective national strategy for ensuring adequate supplies of blood and its products to meet national needs; and ensuring high standards of safety and quality.... national blood authority

Small-bowel Transplantantion

Before the advent of small-bowel transplants, long-term intravenous feeding (total parenteral nutrition or TPN) was the last option for patients with chronic intestinal failure. Most recipients are children, and small-bowel transplantation is currently reserved for patients unable to continue on long-term parenteral nutrition. The main constraints to small-bowel transplantation are the intensity of rejection (necessitating high levels of immunosuppression), and the lack of donors who are the same size as the recipient (a particular problem for children).... small-bowel transplantantion

Blood Bank

a department within a hospital or blood transfusion centre in which blood collected from donors is stored prior to transfusion. Blood must be kept at a temperature of 4°C and may be used up to four weeks after collection.... blood bank

Sperm Bank

a facility that collects, freezes, and stores human sperm for future use in *artificial insemination (see cryopreservation). Sperm is donated by men who relinquish legal rights to any future child, and donors’ identities are generally unknown to recipients. In some cases, men store their sperm for their own future use if they are to undergo a medical treatment that might leave them sterile.... sperm bank

Haemophilia

An inherited disorder of blood COAGULATION which results in prolonged bleeding even after minor injury. There is a de?ciency of factor VIII, an essential clotting factor in the coagulation cascade – the complex series of biochemical events that leads from injury of the wall of a blood vessel to the formation of a blood clot that checks bleeding. Haemophilia is a sex-linked recessive disorder (though a small number of cases arise by spontaneous mutation), so that, if females carry the disease, one-half of their sons will be affected and one-half of their daughters will be carriers. The sons of haemophiliacs are unaffected but one-half of their daughters will be carriers.

Haemophilia affects approximately 1:4,000 of the UK population but only 1:20,000 is severely affected. Severity of the disease depends upon the percentage, compared with normal, of factor VIII activity present. Less than 1 per cent and there will be spontaneous bleeding into joints and muscles; 1–5 per cent and there will be occasional spontaneous bleeding and severe bleeding after minor injury; 5–25 per cent and there will only be severe bleeding after major injury. Before treatment was available, severe haemophiliacs suffered from acute pain and deformity from bleeds into joints and muscles. Bleeding also occurred into the gut, kidneys and brain, and few survived past adolescence.

Freeze-dried factor VIII may be kept in domestic refrigerators. Haemophiliacs can use it to abort minor bleeds by reconstituting it and injecting it intravenously. More major bleeding or preparation for surgery involves raising factor VIII levels to 30–100 per cent by giving cryoprecipitate.

With treatment, most haemophiliacs lead normal lives, although obviously dangerous or contact sports should be avoided. Before donors of blood were screened for HEPATITIS B and C or for HIV infection (see AIDS/HIV), some individuals with haemophilia receiving factor VIII were unwittingly infected with those diseases. Today’s screening procedures make such infections very unlikely.

There is a National Haemophilia Register and each registered sufferer carries a card with details about his or her condition. Information may also be obtained from NHS haemophilia centres and the Haemophilia Society.... haemophilia

Donor

A person who provides blood for transfusion, tissues or organs for transplantation, eggs, or semen for artificial insemination. The organs most frequently donated are kidneys, corneas, heart, lungs, liver, and pancreas. Certain organs can be donated during a person’s lifetime; some are only used following brain death. All donors should be free of cancer, serious infection (such as hepatitis B), and should not carry HIV. Organs for transplantation must be removed within a few hours of brain death, and before or immediately after the heartbeat has stopped. In some kidney transplants, the kidney is provided by a living donor, usually a relative whose body tissues match well on the basis of tissue-typing. Suitable related donors may also provide bone marrow for transplantation and sometimes skin for grafting. (See also artificial insemination; blood donation; bone marrow transplant; organ donation; transplant surgery.)... donor

Organ Donation

The agreement of a person (or his or her family) to surgical removal of one or more organs for use in transplant surgery.

Most organs for transplantation, such as the heart, lungs, liver, and kidneys, are removed immediately after death, often in intensive care units where heart and lung function is sometimes maintained by machine after brain death been certified.

Compatible living donors may also be able to give a kidney (see tissue-typing).

People can facilitate use of their organs after death by informing relatives and carrying a donor card.

(See also corneal graft; heart–lung transplant; heart transplant; heart-valve surgery; kidney transplant; liver transplant.)... organ donation

Stem Cell

A basic cell in the body from which more specialized cells are formed. Stem cells within the bone marrow produce blood cells through a series of maturation steps. Stem cells are found in blood and can be transplanted as an alternative to bone marrow transplantation. Stem cells can be obtained from a donor sibling, a matched but unrelated donor, or from stored umbilical blood. Patients can also act as their own donors, with cells harvested and stored to be reinfused later after treatment has damaged the bone marrow. Stem-cell transplantation is used mainly for people being treated for leukaemia and other cancers but may, in the future, be used for noncancerous disorders.... stem cell

Hepatitis

In?ammation of the LIVER which damages liver cells and may ultimately kill them. Acute injury of the liver is usually followed by complete recovery, but prolonged in?ammation after injury may result in FIBROSIS and CIRRHOSIS. Excluding trauma, hepatitis has several causes:

Viral infections by any of hepatitis A, B, C, D, or E viruses and also CYTOMEGALOVIRUS (CMV), EPSTEIN BARR VIRUS, and HERPES SIMPLEX.

Autoimmune disorders such as autoimmune chronic hepatitis, toxins, alcohol and certain drugs – ISONIAZID, RIFAMPICIN, HALOTHANE and CHLORPROMAZINE.

WILSON’S DISEASE.

Acute viral hepatitis causes damage throughout the liver and in severe infections may destroy whole lobules (see below).

Chronic hepatitis is typi?ed by an invasion of the portal tract by white blood cells (mild hepatitis). If these mononuclear in?ammatory cells invade the body (parenchyma) of the liver tissue, ?brosis and then chronic disease or cirrhosis can develop. Cirrhosis may develop at any age and commonly results in prolonged ill health. It is an important cause of premature death, with excessive alcohol consumption commonly the triggering factor. Sometimes, cirrhosis may be asymptomatic, but common symptoms are weakness, tiredness, poor appetite, weight loss, nausea, vomiting, abdominal discomfort and production of abnormal amounts of wind. Initially, the liver may enlarge, but later it becomes hard and shrunken, though rarely causing pain. Skin pigmentation may occur along with jaundice, the result of failure to excrete the liver product BILIRUBIN. Routine liver-function tests on blood are used to help diagnose the disease and to monitor its progress. Spider telangiectasia (caused by damage to blood vessels – see TELANGIECTASIS) usually develop, and these are a signi?cant pointer to liver disease. ENDOCRINE changes occur, especially in men, who lose their typical hair distribution and suffer from atrophy of their testicles. Bruising and nosebleeds occur increasingly as the cirrhosis worsens, and portal hypertension (high pressure of venous blood circulation through the liver) develops due to abnormal vascular resistance. ASCITES and HEPATIC ENCEPHALOPATHY are indications of advanced cirrhosis.

Treatment of cirrhosis is to tackle the underlying cause, to maintain the patient’s nutrition (advising him or her to avoid alcohol), and to treat any complications. The disorder can also be treated by liver transplantation; indeed, 75 per cent of liver transplants are done for cirrhosis. The overall prognosis of cirrhosis, however, is not good, especially as many patients attend for medical care late in the course of the disease. Overall, only 25 per cent of patients live for ?ve years after diagnosis, though patients who have a liver transplant and survive for a year (80 per cent do) have a good prognosis.

Autoimmune hepatitis is a type that most commonly occurs in women between 20 and 40 years of age. The cause is unknown and it has been suggested that the disease has several immunological subtypes. Symptoms are similar to other viral hepatitis infections, with painful joints and AMENORRHOEA as additional symptoms. Jaundice and signs of chronic liver disease usually occur. Treatment with CORTICOSTEROIDS is life-saving in autoimmune hepatitis, and maintenance treatment may be needed for two years or more. Remissions and exacerbations are typical, and most patients eventually develop cirrhosis, with 50 per cent of victims dying of liver failure if not treated. This ?gure falls to 10 per cent in treated patients.

Viral hepatitis The ?ve hepatic viruses (A to E) all cause acute primary liver disease, though each belongs to a separate group of viruses.

•Hepatitis A virus (HAV) is an ENTEROVIRUS

which is very infectious, spreading by faecal contamination from patients suffering from (or incubating) the infection; victims excrete viruses into the faeces for around ?ve weeks during incubation and development of the disease. Overcrowding and poor sanitation help to spread hepatitis A, which fortunately usually causes only mild disease.

Hepatitis B (HBV) is caused by a hepadna virus, and humans are the only reservoir of infection, with blood the main agent for transferring it. Transfusions of infected blood or blood products, and injections using contaminated needles (common among habitual drug abusers), are common modes of transfer. Tattooing and ACUPUNCTURE may spread hepatitis B unless high standards of sterilisation are maintained. Sexual intercourse, particularly between male homosexuals, is a signi?cant infection route.

Hepatitis C (HCV) is a ?avivirus whose source of infection is usually via blood contacts. E?ective screening of blood donors and heat treatment of blood factors should prevent the spread of this infection, which becomes chronic in about 75 per cent of those infected, lasting for life. Although most carriers do not suffer an acute illness, they must practise life-long preventive measures.

Hepatitis D (HDV) cannot survive independently, needing HBV to replicate, so its sources and methods of spread are similar to the B virus. HDV can infect people at the same time as HBV, but it is capable of superinfecting those who are already chronic carriers of the B virus. Acute and chronic infection of HDV can occur, depending on individual circumstances, and parenteral drug abuse spreads the infection. The disease occurs worldwide, being endemic in Africa, South America and the Mediterranean littoral.

Hepatitis E virus (HEV) is excreted in the stools, spreading via the faeco-oral route. It causes large epidemics of water-borne hepatitis and ?ourishes wherever there is poor sanitation. It resembles acute HAV infection and the patient usually recovers. HEV does not cause chronic infection. The clinical characteristics of the ?ve hepatic

viruses are broadly similar. The initial symptoms last for up to two weeks (comprising temperature, headache and malaise), and JAUNDICE then develops, with anorexia, nausea, vomiting and diarrhoea common manifestations. Upper abdominal pain and a tender enlarged liver margin, accompanied by enlarged cervical lymph glands, are usual.

As well as blood tests to assess liver function, there are speci?c virological tests to identify the ?ve infective agents, and these are important contributions to diagnosis. However, there is no speci?c treatment of any of these infections. The more seriously ill patients may require hospital care, mainly to enable doctors to spot at an early stage those developing acute liver failure. If vomiting is a problem, intravenous ?uid and glucose can be given. Therapeutic drugs – especially sedatives and hypnotics – should be avoided, and alcohol must not be taken during the acute phase. Interferon is the only licensed drug for the treatment of chronic hepatitis B, but this is used with care.

Otherwise-?t patients under 40 with acute viral hepatitis have a mortality rate of around

0.5 per cent; for those over 60, this ?gure is around 3 per cent. Up to 95 per cent of adults with acute HBV infection recover fully but the rest may develop life-long chronic hepatitis, particularly those who are immunode?cient (see IMMUNODEFICIENCY).

Infection is best prevented by good living conditions. HVA and HVB can be prevented by active immunisation with vaccines. There is no vaccine available for viruses C, D and E, although HDV is e?ectively prevented by immunisation against HBV. At-risk groups who should be vaccinated against HBV include:

Parenteral drug abusers.

Close contacts of infected individuals such as regular sexual partners and infants of infected mothers.

Men who have sex with men.

Patients undergoing regular haemodialysis.

Selected health professionals, including laboratory sta? dealing with blood samples and products.... hepatitis

Transfusion

The administration of any ?uid into a person’s vein using a drip. This apparatus facilitates a continuous injection in which the ?uid ?ows by force of gravity from a suspended bottle, via a tube that is ?xed to a hollow needle inserted into a vein (usually in the front of the elbow). Saline solution, PLASMA and whole BLOOD (see below) are the most commonly administered ?uids. Saline is used to restore ?uid to a seriously dehydrated individual (see DEHYDRATION) and may be used as a temporary measure in SHOCK due to blood loss while the appropriate type of blood is being obtained for transfusion. Saline may also be useful as a way of administering a regular supply of a drug over a period of time. Plasma is normally used as a temporary measure in the treatment of shock until appropriately matched blood is available or if for any reason, such as for a patient with severe burns, plasma is preferable to blood.

Transfusion of blood is a technique that has been used since the 17th century – although, until the 20th century, with a subsequent high mortality rate. It was only when incompatibility of BLOOD GROUPS was considered as a potential cause of this high mortality that routine blood-testing became standard practice. Since the National Blood Transfusion Service was started in the United Kingdom (in 1946), blood for transfusion has been collected from voluntary, unpaid donors: this is screened for infections such as SYPHILIS, HIV, HEPATITIS and nvCJD (see CREUTZFELDT-JAKOB DISEASE (CJD)), sorted by group, and stored in blood-banks throughout the country.

In the UK in 2004, the National Blood Authority – today’s transfusion service – announced that it would no longer accept donations from anyone who had received a blood transfusion since 1980 – because of the remote possibility that they might have been infected with the PRION which causes nvCJD.

A standard transfusion bottle has been developed, and whole blood may be stored at 2–6 °C for three weeks before use. Transfusions may then be given of whole blood, plasma, blood cells, or PLATELETS, as appropriate. Stored in the dried form at 4–21 °C, away from direct sunlight, human plasma is stable for ?ve years and is easily reconstituted by adding sterile distilled water.

The National Blood Authority prepares several components from each donated unit of blood: whole blood is rarely used in adults. This permits each product, whether plasma or various red-cell concentrates, to be stored under ideal conditions and used in appropriate clinical circumstances – say, to restore blood loss or to treat haemostatic disorders.

Transfusion of blood products can cause complications. Around 5 per cent of transfused patients suffer from a reaction; most are mild, but they can be severe and occasionally fatal. It can be di?cult to distinguish a transfusion reaction from symptoms of the condition being treated, but the safe course is to stop the transfusion and start appropriate investigation.

In the developed world, clinicians can expect to have access to high-quality blood products, with the responsibility of providing blood resting with a specially organised transfusion service. The cause of most fatal haemolytic transfusion reactions is a clerical error due to faulty labelling and/or failure to identify the recipient correctly. Hospitals should have a strict protocol to prevent such errors.

Arti?cial blood Transfusion with blood from donors is facing increasing problems. Demand is rising; suitable blood donors are becoming harder to attract; the processes of taking, storing and cross-matching donor blood are time-consuming and expensive; the shelf-life is six weeks; and the risk of adverse reactions or infection from transfused blood, although small, is always present. Arti?cial blood would largely overcome these drawbacks. Several companies in North America are now preparing this: one product uses puri?ed HAEMOGLOBIN from humans and another from cows. These provide oxygen-carrying capacity, are unlikely to be infectious and do not provoke immunological rejections. Yet another product, called Oxygene®, does not contain any animal or human blood products; it comprises salt water and a substance called per?ubron, the molecules of which store oxygen and absorb carbon dioxide more e?ectively than does haemoglobin. Within 24 hours of being transfused into a person’s bloodstream, per?ubron evaporates and is harmlessly breathed out by the recipient. Arti?cial blood is especially valuable in that it contains no unwanted proteins that can provoke adverse immunological reactions. Furthermore, it is disease-free, lasts for up to three years and is no more expensive than donor blood. It could well take the place of donor blood within a few years.

Autologous transfusion is the use of an individual’s own blood, provided in advance, for transfusion during or after a surgical operation. This is a valuable procedure for operations that may require large transfusions or where a person has a rare blood group. Its use has increased for several reasons:

fear of infection such as HIV and hepatitis.

shortages of donor blood and the rising cost of units of blood.

substantial reduction of risk of incompatible transfusions. In practice, blood transfusion in the UK is

remarkably safe, but there is always room for improvement. So, in the 1990s, a UK inquiry on the Serious Hazards of Transfusion (SHOT) was launched. It established (1998) that of 169 recently reported serious hazards following blood transfusion, 81 had involved a blood component being given to the wrong patient, while only eight were the result of viral or bacterial infections.

There are three ways to use a patient’s own blood in transfusion:

(1) predeposit autologous donation (PAD) – taking blood from a patient before operation and transfusing this blood back into the patient as required during and after operation.

(2) acute normovalaemic haemodilution (ANH) – diluting previously withdrawn blood and thus increasing the volume before transfusion.

(3) perioperative cell salvage (PCS) – the use of centrifugal cell separation on blood saved during an operation, particularly spinal surgery where blood loss may be considerable.

The government has urged NHS trusts to consider the introduction of PCS as a possible adjunct or alternative to banked-blood transfusion. In one centre (Nottingham), PCS has been used in the form of continuous autologous transfusion for several years with success.

Exchange transfusion is the method of treatment in severe cases of HAEMOLYTIC DISEASE OF THE NEWBORN. It consists of replacing the whole of the baby’s blood with Rh-negative blood of the correct blood group for the baby.... transfusion

Transplantation

Transplantation of tissues or organs of the body are de?ned as an allotransplant, if from another person; an autotransplant, if from the patient him or herself – for example, a skin graft (see GRAFT; SKIN-GRAFTING); and a xenotransplant, if from an animal.

The pioneering success was achieved with transplantation of the kidney in the 1970s; this has been most successful when the transplanted kidney has come from an identical twin. Less successful have been live transplants from other blood relatives, while least successful have been transplants from other live donors and cadaver donors. The results, however, are steadily improving. Thus the one-year functional survival of kidneys transplanted from unrelated dead donors has risen from around 50 per cent to over 80 per cent, and survival rates of 80 per cent after three years are not uncommon. For a well-matched transplant from a live related donor, the survival rate after ?ve years is around 90 per cent. And, of course, if a transplanted kidney fails to function, the patient can always be switched on to some form of DIALYSIS. In the United Kingdom the supply of cadaveric (dead) kidneys for transplantation is only about half that necessary to meet the demand.

Other organs that have been transplanted with increasing success are the heart, the lungs, the liver, bone marrow, and the cornea of the eye. Heart, lung, liver and pancreas transplantations are now carried out in specialist centres. It is estimated that in the United Kingdom, approximately 200 patients a year between the ages of 15 and 55 would bene?t from a liver transplant if an adequate number of donors were available. More than 100 liver transplants are carried out annually in the United Kingdom and one-year-survival rates of up to 80 per cent have been achieved.

The major outstanding problem is how to prevent the recipient’s body from rejecting and destroying the transplanted organ. Such rejection is part of the normal protective mechanism of the body (see IMMUNITY). Good progress has been made in techniques of tissue-typing and immunosuppression to overcome the problem. Drugs are now available that can suppress the immune reactions of the recipient, which are responsible for the rejection of the transplanted organ. Notable among these are CICLOSPORIN A, which revolutionised the success rate, and TACROLIMUS, a macrolide immunosuppressant.

Another promising development is antilymphocytic serum (ALS), which reduces the activity of the lymphocytes (see LYMPHOCYTE) cells which play an important part in maintaining the integrity of the body against foreign bodies.

Donor cards are now available in all general practitioners’ surgeries and pharmacies but, of the millions of cards distributed since 1972, too few have been used. The reasons are complex but include the reluctance of the public and doctors to consider organ donation; poor organisation for recovery of donor kidneys; and worries about the diagnosis of death. A code of practice for procedures relating to the removal of organs for transplantation was produced in 1978, and this code has been revised in the light of further views expressed by the Conference of Medical Royal Colleges and Faculties of the United Kingdom on the Diagnosis of Brain Death. Under the Human Tissue Act 1961, only the person lawfully in possession of the body or his or her designate can authorise the removal of organs from a body. This authorisation may be given orally.

Patients who may become suitable donors after death are those who have suffered severe and irreversible brain damage – since such patients will be dependent upon arti?cial ventilation. Patients with malignant disease or systemic infection, and patients with renal disease, including chronic hypertension, are unsuitable.

If a patient carries a signed donor card or has otherwise recorded his or her wishes, there is no legal requirement to establish lack of objection on the part of relatives – although it is good practice to take account of the views of close relatives. If a relative objects, despite the known request by the patient, sta? will need to judge, according to the circumstances of the case, whether it is wise to proceed with organ removal. If a patient who has died is not known to have requested that his or her organs be removed for transplantation after death, the designated person may only authorise the removal if, having made such reasonable enquiry as may be practical, he or she has no reason to believe (a) that the deceased had expressed an objection to his or her body being so dealt with after death, or (b) that the surviving spouse or any surviving relative of the deceased objects to the body being so dealt with. Sta? will need to decide who is best quali?ed to approach the relatives. This should be someone with appropriate experience who is aware how much the relative already knows about the patient’s condition. Relatives should not normally be approached before death has occurred, but sometimes a relative approaches the hospital sta? and suggests some time in advance that the patient’s organs might be used for transplantation after death. The sta? of hospitals and organ exchange organisations must respect the wishes of the donor, the recipient and their families with respect to anonymity.

Relatives who enquire should be told that some post-mortem treatment of the donor’s body will be necessary if the organs are to be removed in good condition. It is ethical (see ETHICS) to maintain arti?cial ventilation and heartbeat until removal of organs has been completed. This is essential in the case of heart and liver transplants, and many doctors think it is desirable when removing kidneys. O?cial criteria have been issued in Britain to recognise when BRAIN-STEM DEATH has occurred. This is an important protection for patients and relatives when someone with a terminal condition

– usually as a result of an accident – is considered as a possible organ donor.... transplantation

Tissue-typing

The classification of certain characteristics of the tissues of prospective organ donors and recipients (see transplant surgery). This minimizes the risk of rejection of a donor organ by the recipient’s immune system.

A person’s tissue type is classified in terms of their histocompatibility antigens, the most important of which are the human leukocyte antigens (HLAs), on the surface of cells. A person’s set of HLAs is inherited and unique (except for identical twins, who have the same set). Nevertheless, close relatives often have closely matching types. A person’s tissue-type is established by laboratory tests on cells from a blood sample. In one method, an antiserum containing antibodies to a particular is added to the test specimen. If the is present, it is detected by an observable colour or other change.... tissue-typing


Health encyclopedia icon Health Encyclopedia

Recent Searches